We recently updated our Privacy Notice and Terms of Use.
Med-IQ
<em>Decision-IQ:</em> Genetic Risk Assessment and Testing for Hereditary Ovarian Cancer
Decision-IQ Decision-IQ

Decision-IQ: Genetic Risk Assessment and Testing for Hereditary Ovarian Cancer


This activity was developed by Med-IQ in collaboration with Duke University Health System Department of Clinical Education and Professional Development.

Med-IQ      Duke Medicine
 

Released:
1/31/18
Expires:
1/30/19

Maximum Credits:

0.25
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Decision-IQ Decision-IQ
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
1/31/18

Expires:
1/30/19

Maximum Credits:
0.25
Decision-IQ Decision-IQ
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
1/31/18
Expires:
1/30/19


Maximum Credits:
0.25


Overview: In this brief case-based activity, meet Karen, a fictional 30-year-old woman whose mother recently died of ovarian cancer. Karen is now asking whether she should undergo genetic testing or ovarian cancer screening. As you move through this activity, read through links to useful resources to help you make clinical management decisions for Karen. You will also receive insights from expert faculty Andrew Berchuck, MD, on the latest recommendations for genetic testing and risk-reducing strategies for hereditary ovarian cancer.

CME Information:

Faculty
Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Duke University School of Medicine
Durham, NC            
 
Activity Planners
Noah D. Kauff, MD
Director, Clinical Cancer Genetics
Duke Cancer Institute
Durham, NC

Jaime Symowicz, PhD
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD
 
Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN
Manager
Lead Nurse Planner
Med-IQ
East Lansing, MI
 
Learning Objectives
Upon completion, participants should be able to:

  • Summarize the recommendations from the 2017 ACOG/SGO clinical management guidelines on genetic testing and risk-reducing strategies for hereditary ovarian cancer

Target Audience
This activity is intended for community gynecologists and oncologists.
 
Series Overview/Statement of Need
Approximately 9% to 24% of epithelial ovarian cancer cases are caused by germline mutations in BRCA1 or BRCA2 genes. Many women are often not referred to genetic counselors for genetic risk assessment and testing. Furthermore, many healthcare providers are not familiar with guideline recommendations on risk-reducing surgeries. For these reasons, gynecologists and oncologists need to be aware of the updated 2017 American College of Obstetricians and Gynecologists/Society of Gynecologic Oncology clinical management guidelines on genetic testing and risk-reducing strategies for hereditary ovarian cancer.
 
Collaborator Statement
This activity was developed by Med-IQ in collaboration with Duke University Health System Department of Clinical Education and Professional Development.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: January 31, 2018
Expiration Date: January 30, 2019
Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Andrew Berchuck, MD
Consulting fees/advisory boards: Merck & Co., Inc.
 
The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information       
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.
 
Hardware/Software Requirements

Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/
 
Google Chrome - latest version
Download: http://www.google.com/chrome
 
Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/ 
 
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support
 
ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.

Copyright
© 2018 Med-IQ, Inc. and Duke University Health System